Improving Safe and Effective Use of Drugs in Pregnancy and Lactation

Workshop Summary

Laura E. Riley, Alison G. Cahill, Richard Beigi, Renate Savich, George Saade

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In February 2015, given high rates of use of medications by pregnant women and the relative lack of data on safety and efficacy of many drugs utilized in pregnancy, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine (SMFM), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics (AAP) convened a group of experts to review the “current” state of the clinical care and science regarding medication use during the perinatal period. The expert panel chose select medications to demonstrate what existing safety and efficacy data may be available for clinicians and patients when making decisions about use in pregnancy or lactation. Furthermore, these example medications also provided opportunities to highlight where data are lacking, thus forming a list of research gaps. Last, after reviewing the existing vaccine safety surveillance system as well as the legislative history surrounding the use of drugs for pediatric diseases, the expert panel made specific recommendations concerning policy efforts to stimulate more research and regulatory attention on drugs for pregnant and lactating women.

Original languageEnglish (US)
JournalAmerican Journal of Perinatology
DOIs
StateAccepted/In press - Dec 27 2016

Fingerprint

Lactation
Safety
Education
Pregnancy
Pregnant Women
National Institute of Child Health and Human Development (U.S.)
Pharmaceutical Preparations
Pediatrics
Research
Decision Making
Vaccines
History

Keywords

  • drug safety
  • drug surveillance
  • lactation
  • pharmacokinetics
  • pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Improving Safe and Effective Use of Drugs in Pregnancy and Lactation : Workshop Summary. / Riley, Laura E.; Cahill, Alison G.; Beigi, Richard; Savich, Renate; Saade, George.

In: American Journal of Perinatology, 27.12.2016.

Research output: Contribution to journalArticle

@article{c8c2a6f1877f443196558f9f1a5f759a,
title = "Improving Safe and Effective Use of Drugs in Pregnancy and Lactation: Workshop Summary",
abstract = "In February 2015, given high rates of use of medications by pregnant women and the relative lack of data on safety and efficacy of many drugs utilized in pregnancy, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine (SMFM), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics (AAP) convened a group of experts to review the “current” state of the clinical care and science regarding medication use during the perinatal period. The expert panel chose select medications to demonstrate what existing safety and efficacy data may be available for clinicians and patients when making decisions about use in pregnancy or lactation. Furthermore, these example medications also provided opportunities to highlight where data are lacking, thus forming a list of research gaps. Last, after reviewing the existing vaccine safety surveillance system as well as the legislative history surrounding the use of drugs for pediatric diseases, the expert panel made specific recommendations concerning policy efforts to stimulate more research and regulatory attention on drugs for pregnant and lactating women.",
keywords = "drug safety, drug surveillance, lactation, pharmacokinetics, pregnancy",
author = "Riley, {Laura E.} and Cahill, {Alison G.} and Richard Beigi and Renate Savich and George Saade",
year = "2016",
month = "12",
day = "27",
doi = "10.1055/s-0037-1598070",
language = "English (US)",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",

}

TY - JOUR

T1 - Improving Safe and Effective Use of Drugs in Pregnancy and Lactation

T2 - Workshop Summary

AU - Riley, Laura E.

AU - Cahill, Alison G.

AU - Beigi, Richard

AU - Savich, Renate

AU - Saade, George

PY - 2016/12/27

Y1 - 2016/12/27

N2 - In February 2015, given high rates of use of medications by pregnant women and the relative lack of data on safety and efficacy of many drugs utilized in pregnancy, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine (SMFM), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics (AAP) convened a group of experts to review the “current” state of the clinical care and science regarding medication use during the perinatal period. The expert panel chose select medications to demonstrate what existing safety and efficacy data may be available for clinicians and patients when making decisions about use in pregnancy or lactation. Furthermore, these example medications also provided opportunities to highlight where data are lacking, thus forming a list of research gaps. Last, after reviewing the existing vaccine safety surveillance system as well as the legislative history surrounding the use of drugs for pediatric diseases, the expert panel made specific recommendations concerning policy efforts to stimulate more research and regulatory attention on drugs for pregnant and lactating women.

AB - In February 2015, given high rates of use of medications by pregnant women and the relative lack of data on safety and efficacy of many drugs utilized in pregnancy, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine (SMFM), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics (AAP) convened a group of experts to review the “current” state of the clinical care and science regarding medication use during the perinatal period. The expert panel chose select medications to demonstrate what existing safety and efficacy data may be available for clinicians and patients when making decisions about use in pregnancy or lactation. Furthermore, these example medications also provided opportunities to highlight where data are lacking, thus forming a list of research gaps. Last, after reviewing the existing vaccine safety surveillance system as well as the legislative history surrounding the use of drugs for pediatric diseases, the expert panel made specific recommendations concerning policy efforts to stimulate more research and regulatory attention on drugs for pregnant and lactating women.

KW - drug safety

KW - drug surveillance

KW - lactation

KW - pharmacokinetics

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85011662377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011662377&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1598070

DO - 10.1055/s-0037-1598070

M3 - Article

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

ER -